IR Information

Timely Disclosure

Onconova Therapeutics announces the synergistic anti-cancer activity of rigosertib combined with immune checkpoint blockade Convocation
Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox Convocation
New Patent Issued in Japan for Antiviral Agent Brincidofovir Convocation
Chugai receives NHI price listing for polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma Convocation
Notice of Appointment of Corporate Officer Convocation
Summary of Financial Statements for the First Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated) Convocation
SymBio submits a partial change application for use of TREAKISYM Liquid Formulation for Rapid Infusion (RI) administration Convocation
SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma Convocation
SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma Convocation
U.S. Food and Drug Administration granted fast track designation to antiviral agent brincidofovir IV for the treatment of adenovirus infection in pediatric patients Convocation
Onconova Therapeutics announces first patient dosed in an investigator-initiated Phase 2 study of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
SymBio submits partial change application to extend the shelf life of TREAKISYM Ready-To-Dilute (RTD) Formulation Convocation
Notice of Shareholder Voting Results for the16th Ordinary General Meeting of Shareholders Convocation
SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma Convocation
SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma Convocation
Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers Convocation
Notice Concerning the Issuance of Stock Acquisition Rights to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights to Employees Convocation
SymBio receives approval for use of TREAKISYM in combination with rituximab and polatuzumab vedotin as treatment for relapsed or refractory diffuse large B-cell lymphoma Convocation
SymBio receives approval for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma Convocation
SymBio submits IND Application for Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV for treatment of Pediatric Adenovirus Infection Convocation
Chimerix Announces FDA Extends PDUFA Date of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox to July 7, 2021 Convocation
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board Convocation
Results of Phase III Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Convocation
3 Year Mid-Range Plan: FY 2021 to FY 2023 Convocation
Notice Concerning Non-Operating Income Convocation
Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated) Convocation
Collaborative research with the Institute of Medical Science, the University of Tokyo, to explore new indications for bendamustine and rigosertib Convocation
Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation Convocation
Notice of Appointment of Corporate Officer Convocation
Notice of Conclusion of Syndicated Loan Agreement Convocation
Completion, Monthly Exercise Status and Large Volume Exercise of the 51th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Commencement of in-house sales of the anti-cancer agent Treakisym Convocation
Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox Convocation
Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
National Health Insurance (NHI) Price Listing and Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation Convocation
Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Chimerix Completed Rolling Submission of New Drug Application to FDA for Brincidofovir as a Medical Countermeasure for Smallpox Convocation
Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Exercise of the 51st Stock Acquisition Rights and Revision to the Specific Uses and Amounts of Funds Raised through the 50th and 51st Stock Acquisition Rights Convocation
SymBio Receives Approval of TREAKISYM Ready-To-Dilute (RTD) Formulation Convocation
Revision to Earnings Forecasts for FY 2020 and Mid-Range Plan (FY 2020 to FY 2022) Convocation
Last Patient Last Visit (“LPLV”) Achieved in Clinical Study for TREAKISYM Rapid Infusion Liquid Formulation Convocation
Preparation for Sales & Marketing by SymBio's Own Sales Organization Convocation
Final Arbitration Award in Dispute against The Medicines Company Convocation
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial for Higher-Risk Myelodysplastic Syndromes (HR-MDS) Convocation
Arbitration Award in Dispute against The Medicines Company Convocation
Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
SymBio Announces Global Development Plan of Anti-viral Drug Brincidofovir IV For Adenovirus Infectious DiseaseAfter Hematopoietic Stem Cell Transplantation Convocation
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis Convocation
Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease Convocation
SymBio submits Partial Change Application for use of TREAKISYM in combination with polatuzumab vedotin and rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma Convocation
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS Convocation
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma Convocation
Completion, Monthly Exercise Status and Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
The 25th Congress of the European Hematology Association (25th EHA Annual Congress) Accepts Abstract for Phase III Clinical Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma for Publication Convocation
SymBio submits Partial Change Application for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma Convocation
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox Convocation
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees Convocation
Notice of Change (Retirement) of Director Convocation
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of Shareholder Voting Results for the 15th Ordinary General Meeting of Shareholders Convocation
Notice of Members of the Board of Director, Substitute Member of the Audit & Supervisory Board and Corporate Officers Appointment Convocation
Notice Concerning the Issuance of Stock Acquisition Rights to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights to Employees Convocation
Completion of Patient Enrollment in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation Convocation
Onconova Announces Completion of Enrollment in Phase 3 INSPIRE Trial of IV Rigosertib Convocation
Completion of Payment for Subscription for the 50th and 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Convocation
Notice of the Issuance of the 50th and 51st Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program) Convocation
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board Convocation
Completion, Monthly Exercise Status and Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
3 Year Mid-Range Plan: FY 2020 to FY 2022 Convocation
Notice Concerning Non-operating Expenses Convocation
Summary of Financial Statements for the Fiscal Year Ended December 31, 2019[Japanese GAAP] (Non-consolidated) Convocation
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of Appointment of Corporate Officer Convocation
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Onconova Announces Data from the INSPIRE Trial and Updated Oral Rigosertib Data at the American Society of Hematology (ASH) 2019 Annual Meeting Convocation
Onconova Announces Collaboration with Inceptua for Pre-approval Access to Anti-cancer Drug Rigosertib Convocation
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of Instruction for Front-Loading Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment and Conclusion of Amendment Agreement Convocation
Summary of Financial Statements for the first nine months of fiscal year ending December 31, 2019 [Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2019 ASH Annual Meeting & Exposition Convocation
SymBio Announces Achievement of Primary Endpoint (Overall Response Rate) in Phase 3 Clinical Trial of TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma Convocation
Onconova Provides Update on the Global Phase 3 INSPIRE Trial of Rigosertib in Myelodysplastic Syndromes and on Future Clinical Trial Plans Convocation
SymBio Announces Exclusive Global License Agreement with Chimerix for Antiviral Drug, Brincidofovir Convocation
SymBio Submits New Drug Application for TREAKISYM Ready-To-Dilute (RTD) Formulation Convocation
Progress (LPLV) of Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma Convocation
Revision to Earnings Forecasts for FY 2019 and Mid-Range Plan (FY 2019 to FY 2022) Convocation
Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Notice Regarding Sale of Fractional Shares Due to Reverse Stock Split Convocation
Completion, Monthly Exercise Status and Large Volume Exercise of the 46th Stock Acquisition Rights(with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of Change (Resignation) of Representative Director and Appointment of Corporate Officer Convocation
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Launch of "Regenerative Medicine" Products that can be used with the anti-cancer drug TREAKISYM as a pretreatment agent Convocation
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
First patient enrolled in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation Convocation
Completion of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma Convocation
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Onconova Announces Over 75 Percent of Planned Enrollment Achieved in Phase 3 INSPIRE Study of Rigosertib Convocation
Notice of Shareholder Voting Results for the 14th Ordinary General Meeting of Shareholders Convocation
Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation Convocation
Notice Concerning the Issuance of Stock Acquisition Rights to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights to Employees Convocation
Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments Convocation
TREAKISYM Approved for use as a Pretreatment to Adoptive T-Cell Therapy Convocation
Notice of Instruction for Front-Loading Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
(Correction Notice of Press Release) Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation Convocation
Notice Regarding Reverse Stock Split and Partial Amendment to Articles of Incorporation Convocation
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board Convocation
SymBio's Mid-Range Plan: FY 2019 to FY 2022 (Four Years) Convocation
Notice Concerning Non-operating Expenses Convocation
Summary of Financial Statements for the Fiscal Year Ended December 31, 2018[Japanese GAAP] (Non-consolidated) Convocation
Onconova Announces Submission of Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib Convocation
Shipments of the 25mg Presentation of Anti-cancer Drug TREAKISYM Intravenous Infusion Paused and Shipment of Substitute Convocation
Completion of Exercise of the 39th Stock Acquisition Rights Issued by way of Third Party Allotment Convocation
Onconova Presents Results from Phase 2 Trial of Oral Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2018 Meeting Convocation
Clinical Trial Begins for TREAKISYM Liquid Formulation(Rapid Infusion Injection Formulation) Convocation
Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2018 ASH Annual Meeting & Exposition Convocation
Onconova Announces Issuance of a New U.S. Patent for Rigosertib Convocation
SymBio Begins Preparation for Own Sales Organization for the Anti-Cancer Agent TREAKISYM Convocation
Completion and Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
SymBio files Partial Change Application for use of TREAKISYM as a Pretreatment to Regenerative Medical Products Convocation
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Launch of New Anti-CD20 Antibodies that can be used in combination with the anti-cancer agent TREAKISYM Convocation
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Notice Concerning Non-operating Expenses Convocation
Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated) Convocation
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Revised Medical Practice Guidelines 2018 for Healthcare Professionals Convocation
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Eagle Announces New Patent Issued for Bendamustine Hydrochloride Injection in the U.S. Convocation
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
TREAKISYM Receives Approval for Combined Use with Anti-CD20 Antibodies Convocation
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Eagle Announces U.S. Court Decision Granting Orphan Drug Exclusivity for Bendamustine Hydrochloride Injection in the U.S. Convocation
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
First Patient Enrolled in Phase 1 Clinical Trial for Oral TREAKISYM for Progressive Solid Tumors Convocation
TREAKISYM Sales Forecast for FY2018 Convocation
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Initiation of Collaborative Research with Keio University on TREAKISYM for Systemic Lupus Erythematosus Convocation
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment Convocation
(Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
(Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Completion of Payment for Subscription for the 45th through 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Convocation
TREAKISYM Achieves 50% Market Share for 1st Line Low Grade Non-Hodgkin Lymphoma Convocation
Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Commit Issue Program) and Conclusion of an Unsecured Loan Facility Agreement  Convocation
Notice of Shareholder Voting Results for the 13th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Issuance of Stock Acquisition Rights to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights to Employees Convocation
Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments Convocation
Termination of the Development of the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
SymBio's Mid-Range Plan: FY2018 to FY2021 Convocation
Summary of Financial Statements for the Fiscal Year Ended December 31, 2017 [Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-Operating Income Convocation
Initiation of Phase 1 Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors Convocation
Onconova Announces Plans for the Global Randomized Phase 3 Trial of IV Rigosertib after Promising Interim Analysis Convocation
Initiation of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma Convocation
Termination of License Agreement between SymBio Pharmaceuticals Limited and The Medicines Company Convocation
Initiation of an Arbitration against The Medicines Company Convocation
Notice Concerning Non-operating Income Convocation
Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2017 [Japanese GAAP] (Non-consolidated) Convocation
Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting Convocation
Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes Convocation
Notice of Revision to the Earnings Forecast for FY2017 Convocation
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited Convocation
Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma Convocation
Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM Convocation
Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment Convocation
Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment Convocation
Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Notice Concerning Non-operating Income Convocation
Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated) Convocation
Onconova Announces Establishment of Collaborative Research and Clinical Program Evaluating Rigosertib in Pediatric "RASopathies" Convocation
Initiation in Japan of the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes Convocation
SEC Filing by The Medicines Company as the Licensor of the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Temporary Suspension of New Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice of Shareholder Voting Results for the 12th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees Convocation
Notice of Appointment of Members of the Board of Directors, Members of the Audit & Supervisory Board, and the Corporate Officers Convocation
Notice concerning the Appointment of the Representative Director and Nominations for the Board of Directors/ Auditor Candidates Convocation
Notice of Change to Use of Funds from the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights Issued by Third-Party Allotment Convocation
SymBio's Mid-Range Plan: FY2017 to FY2019 Convocation
Summary of Financial Statements for the Fiscal Year Ended December 31, 2016[Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-Operating Income Convocation
Expiration of the Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule Convocation
Japan Launch of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg Convocation
Approval in Japan of the Anti-cancer Drug TREAKISYM® for the Additional Indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Convocation
Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting Convocation
Initiation of Patient Enrollment in the Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Notice of Shareholder Voting Results for the Extraordinary Shareholders' Meeting Convocation
Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated) Convocation
Notice concerning Non-operating Expenses Convocation
Notice concerning the Change in Major and Largest Shareholder among the Company's Major Stockholders Convocation
Approval in Japan of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg Convocation
Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes Convocation
Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting Convocation
Notice concerning Partial Amendment to the Articles of Incorporation Convocation
Approval of the Anti-cancer Drug TREAKISYM® for the Additional Indication of Chronic Lymphocytic Leukemia Convocation
Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3 Trial of IV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS) Convocation
Announcement on Achievement of a Sales Milestone for Bendamustine, an Anticancer Agent, in Taiwan, and Receipt of a Milestone Payment related thereto Convocation
Onconova Announces Presentation of Clinical Data from Oral Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting Convocation
Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Notice concerning the Change of Major Shareholder Convocation
Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting Convocation
Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting Convocation
Notice concerning the Change of Major Shareholder Convocation
Notice concerning the Change of Major Shareholder Convocation
Notice concerning Cancellation of the Extraordinary Shareholders' Meeting on July 15, 2016 and Cancellation of the Record Date therefor Convocation
Notice concerning the Change of Major and Largest Shareholder among the Company's Major Stockholders Convocation
SymBio Announces Incorporation of its U.S. Subsidiary Convocation
Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting Convocation
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Completion of Payment for Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice of the Issuance of and the Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment Convocation
(Correction) Notice concerning partial correction to the "Notice of Appointment of Directors" Convocation
Notice of Shareholder Voting Results for the 11th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees Convocation
Notice of Appointment of Directors Convocation
Notice concerning Partial Amendment to the Articles of Incorporation and Nomination of Director Candidates Convocation
Onconova Announces Publication of Results from the ONTIME Trial for rigosertib in MDS Convocation
SymBio's Long Range Plan: FY2016 to FY2018 Convocation
Notice Concerning Non-operating Expenses Convocation
SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule Convocation
Assessment Status of Bendamustine in Europe Convocation
SymBio starts Global Phase 3 Trial for IV Rigosertib Convocation
SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL Convocation
SymBio Files Supplemental NDA for TREAKISYM® in Chronic Lymphocytic Leukemia (Additional Indication) Convocation
SymBio Files Supplemental NDA for TREAKISYM® in a 25mg Vial (Different Strength) Convocation
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients Convocation
Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib Convocation
Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS Convocation
SymBio Partner Announces European Approval of IONSYS® Convocation
Notice Concerning Non-operating Expenses Convocation
Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS Convocation
Completion of TREAKISYM® Phase II Trial in Chronic Lymphocytic Leukemia Convocation
SymBio to Participate in Global Phase 3 Trial for IV Rigosertib Convocation
SymBio and The Medicines Company (Nasdaq: MDCO), announce the establishment of a strategic partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan. Convocation
Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS Convocation
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients Convocation
Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS Convocation
Notice Concerning Non-operating income Convocation
Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS Convocation
Notice Concerning Non-operating Expense Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice of Shareholder Voting Results for the 10th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees Convocation
Notice of Director and Auditor Appointments Convocation
Notice Concerning Change in Status of Major shareholder Convocation
Notice of Nomination of Director Candidates and Auditor Candidates Convocation
SymBio's Long Range Plan: FY2015 to FY2017 Convocation
Notice Concerning Non-Operating Income Convocation
Establishment of Sponsored ADR (American Depositary Receipt) Program Convocation
SEC filings for Establishment of Sponsored ADR (American Depositary Receipt) Program Convocation
Notice of Revision of the Long Range Plan: FY2014 to FY2016 Convocation
SymBio's Long Range Plan: FY2014 to FY2016 (Revised Version) Convocation
Completion of Payment for Subscription of the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment Convocation
Notice of the Subscription for the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment Convocation
Notice of Revision of the Financial Forecast for FY2014 Convocation
Notice Concerning Non-Operation Income Convocation
Notice Concerning Change in Status of Major shareholder Convocation
Notice Concerning Relocation of Head Office Convocation
Notice Concerning Non-Operation Expense Convocation
SymBio Announces Korea NDA Approval of Additional Indication for Bendamustine Hydrochloride (SyB L-0501) Convocation
Notice Concerning Non-Operation Expense Convocation
Notice Concerning Adjustment to Exercise Price of Stock Option Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees Convocation
Notice of Shareholder Voting Results for the 9th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Appointment of Directors Convocation
Notice Concerning the Partial Amendment to the Articles of Incorporation and Election of Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors Convocation